So-Young Q2 revenue surges 33% but profitability remains the open question

What happened

So-Young reported Q2 2026 total revenues of RMB505.2 million, up 33.4% year over year, continuing the clinic-driven top-line expansion. The release provides only revenue figures, omitting net income, cash balance, center count, franchising progress, or CFO status—all key monitoring points from our prior analysis. This revenue growth was already anticipated given the rapid scaling of branded aesthetic centers, but it does not address the widening losses and cash draw seen through Q3 2025. Without profit and cash data, the release cannot confirm whether operating leverage is finally materializing. Investors should seek management commentary and full results to assess whether consolidated loss narrowing and cash stabilization occurred.

Implication

The 33.4% revenue growth likely reflects continued clinic expansion, but the company has not demonstrated that this growth translates into consolidated profitability or stops the cash burn seen through Q3 2025. Key unresolved items from our prior report include whether the 50-center year-end target was met, whether franchising remains immaterial, and whether a permanent CFO has been appointed. Without these details, the investment case still hinges on proving operating leverage and governance stability. We maintain a WAIT rating and would only consider upgrading if subsequent disclosures show substantial loss reduction or cash balance stability, while a downgrade would follow if losses widen further or cash falls below RMB800 million.

Thesis delta

The revenue print confirms continued clinic-driven top-line expansion, which was already anticipated. However, the absence of profit and cash metrics prevents any change to our thesis that SY remains a binary bet on operating leverage. The thesis does not shift; we still require evidence of consolidated loss narrowing and cash stabilization before turning constructive.